**INSERT LOGO HERE**

**[Insert date]**

**[Insert name and address]**

Dear XXXXX,

**(Insert Facility Name)** is pleased to announce that we are now offering Ultrasound Derived Fat Fraction (UDFF) to complement our routine ultrasounds. UDFF is a unique tool that quantifies the amount of fat in a patient’s liver quickly and painlessly during an abdominal ultrasound. This newly acquired technology, available on the ACUSON Sequoia™ ultrasound system, provides non-invasive, cost-effective access to quantitative data needed to successfully evaluate the liver and manage patients.

**Improve patient outcomes with early detection**

Early assessment and characterization of liver steatosis is key to overall disease management and improved patient outcomes. Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common cause of chronic liver disease globally.1,2 In most early cases, patients have no symptoms. However, over time, prolonged and continuous fat build-up within hepatocytes creates a cycle of constant injury and repair. This persistent cycle can lead to more severe and permanent liver conditions. What was once a reversible state of simple steatosis can progress to steatohepatitis, fibrosis, and eventually, cirrhosis or liver failure. Early detection of hepatic steatosis improves the chances of managing or reversing the condition before irreversible changes occur.1

**Offering a non-invasive method to assess liver fat content**

Conventional ultrasound offers a qualitative assessment of hepatic steatosis, which can be subjective and lead to increased variability. Ultrasound Derived Fat Fraction (UDFF) eliminates variability by providing a quantitative, numerical evaluation of liver fat. The ACUSON Sequoia is the only ultrasound technology to classify hepatic steatosis as an index value greater than 5%\*. UDFF delivers similar clinical utility to MRI Proton Density Fat Fraction (PDFF) for determining hepatic steatosis without the high cost or limitations associated with MRI. When combined with

With UDFF, physicians now have a new, non-invasive, cost-effective test to help manage adult patients\*\* with hepatic steatosis. When combined with Automated Shear wave (Auto pSWE) we can reduce elastography screening time, with less variability, providing clinicians with a comprehensive liver assessment in minutes.

**(Insert Facility Name)** is proud to provide this innovative system to you and your patients. To learn more about the ACUSON Sequoia and how it may help your patients, please contact us at **[phone number]** or visit siemens-healthineers.us/sequoia.

Best wishes,

**[Facility name]**

\*Disclaimer \*As of November 22, 2021

\*\*When used as part of an overall assessment of hepatic steatosis

1 Labyed & Milkowski 2021; JUM 39(12) p2427-2428, doi:10.1002/jum.15364

2 Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, Wai-Sun Wong V, Yilmaz Y, George J, Fan J, Vos MB. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology. 2019 Jun;69(6):2672-2682. doi: 10.1002/hep.30251. PMID: 30179269.